131 related articles for article (PubMed ID: 37482138)
21. Differential expression of the alpha2 chain of the interleukin-13 receptor in metastatic human prostate cancer ARCaPM cells.
He H; Xu J; Nelson PS; Marshall FF; Chung LW; Zhau HE; He D; Wang R
Prostate; 2010 Jun; 70(9):993-1001. PubMed ID: 20166133
[TBL] [Abstract][Full Text] [Related]
22. Interleukin 13 mutants of enhanced avidity toward the glioma-associated receptor, IL13Ralpha2.
Madhankumar AB; Mintz A; Debinski W
Neoplasia; 2004; 6(1):15-22. PubMed ID: 15068667
[TBL] [Abstract][Full Text] [Related]
23. An IL13Rα2 peptide exhibits therapeutic activity against metastatic colorectal cancer.
Bartolomé RA; Jaén M; Casal JI
Br J Cancer; 2018 Oct; 119(8):940-949. PubMed ID: 30318506
[TBL] [Abstract][Full Text] [Related]
24. ARA-linker-TGFαL3: a novel chimera protein to target breast cancer cells.
Ghadaksaz A; Imani Fooladi AA; Mahmoodzadeh Hosseini H; Nejad Satari T; Amin M
Med Oncol; 2021 Jul; 38(8):96. PubMed ID: 34273028
[TBL] [Abstract][Full Text] [Related]
25. Analysis of the cancer genome atlas (TCGA) database identifies an inverse relationship between interleukin-13 receptor α1 and α2 gene expression and poor prognosis and drug resistance in subjects with glioblastoma multiforme.
Han J; Puri RK
J Neurooncol; 2018 Feb; 136(3):463-474. PubMed ID: 29168083
[TBL] [Abstract][Full Text] [Related]
26. Interleukin-13 receptor alpha2 is a novel therapeutic target for human adrenocortical carcinoma.
Jain M; Zhang L; He M; Patterson EE; Nilubol N; Fojo AT; Joshi B; Puri R; Kebebew E
Cancer; 2012 Nov; 118(22):5698-708. PubMed ID: 22570059
[TBL] [Abstract][Full Text] [Related]
27. Analysis of antitumor activity of an interleukin-13 (IL-13) receptor-targeted cytotoxin composed of IL-13 antagonist and Pseudomonas exotoxin.
Kioi M; Kawakami K; Puri RK
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6231-8. PubMed ID: 15448012
[TBL] [Abstract][Full Text] [Related]
28. Foretinib induces G2/M cell cycle arrest, apoptosis, and invasion in human glioblastoma cells through c-MET inhibition.
Gortany NK; Panahi G; Ghafari H; Shekari M; Ghazi-Khansari M
Cancer Chemother Pharmacol; 2021 Jun; 87(6):827-842. PubMed ID: 33688998
[TBL] [Abstract][Full Text] [Related]
29. Characterization and Functional Analysis of scFv-based Chimeric Antigen Receptors to Redirect T Cells to IL13Rα2-positive Glioma.
Krenciute G; Krebs S; Torres D; Wu MF; Liu H; Dotti G; Li XN; Lesniak MS; Balyasnikova IV; Gottschalk S
Mol Ther; 2016 Feb; 24(2):354-363. PubMed ID: 26514825
[TBL] [Abstract][Full Text] [Related]
30. Growth-inhibitory effects of TGFαL3-SEB chimeric protein on colon cancer cell line.
Maleki F; Sadeghifard N; Hosseini HM; Bakhtiyari S; Goleij Z; Behzadi E; Sedighian H; Imani Fooladi AA
Biomed Pharmacother; 2019 Feb; 110():190-196. PubMed ID: 30471512
[TBL] [Abstract][Full Text] [Related]
31. Targeting of interleukin-13 receptor on human renal cell carcinoma cells by a recombinant chimeric protein composed of interleukin-13 and a truncated form of Pseudomonas exotoxin A (PE38QQR).
Puri RK; Leland P; Obiri NI; Husain SR; Kreitman RJ; Haas GP; Pastan I; Debinski W
Blood; 1996 May; 87(10):4333-9. PubMed ID: 8639793
[TBL] [Abstract][Full Text] [Related]
32. Interleukin 13 receptor alpha 2 (IL13Rα2): Expression, signaling pathways and therapeutic applications in cancer.
Jaén M; Martín-Regalado Á; Bartolomé RA; Robles J; Casal JI
Biochim Biophys Acta Rev Cancer; 2022 Sep; 1877(5):188802. PubMed ID: 36152905
[TBL] [Abstract][Full Text] [Related]
33. Diphtheria toxin-epidermal growth factor fusion protein and Pseudomonas exotoxin-interleukin 13 fusion protein exert synergistic toxicity against human glioblastoma multiforme cells.
Liu TF; Willingham MC; Tatter SB; Cohen KA; Lowe AC; Thorburn A; Frankel AE
Bioconjug Chem; 2003; 14(6):1107-14. PubMed ID: 14624623
[TBL] [Abstract][Full Text] [Related]
34. RGD and interleukin-13 peptide functionalized nanoparticles for enhanced glioblastoma cells and neovasculature dual targeting delivery and elevated tumor penetration.
Gao H; Xiong Y; Zhang S; Yang Z; Cao S; Jiang X
Mol Pharm; 2014 Mar; 11(3):1042-52. PubMed ID: 24521297
[TBL] [Abstract][Full Text] [Related]
35. Cytokine induction of VCAM-1 but not IL13Rα2 on glioma cells: a tale of two antibodies.
Mahadev V; Starr R; Wright SL; Martinez C; Jensen MC; Barish ME; Forman SJ; Brown CE
PLoS One; 2014; 9(5):e95123. PubMed ID: 24787244
[TBL] [Abstract][Full Text] [Related]
36. Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape.
Hegde M; Mukherjee M; Grada Z; Pignata A; Landi D; Navai SA; Wakefield A; Fousek K; Bielamowicz K; Chow KK; Brawley VS; Byrd TT; Krebs S; Gottschalk S; Wels WS; Baker ML; Dotti G; Mamonkin M; Brenner MK; Orange JS; Ahmed N
J Clin Invest; 2016 Aug; 126(8):3036-52. PubMed ID: 27427982
[TBL] [Abstract][Full Text] [Related]
37. A Novel Recombinant Modified Vaccinia Ankara Virus expressing Interleukin-13 Receptor α2 Antigen for Potential Cancer Immunotherapy.
Sato Y; Vatsan R; Joshi BH; Husain SR; Puri RK
Curr Mol Med; 2023 Mar; ():. PubMed ID: 36999709
[TBL] [Abstract][Full Text] [Related]
38. Alanine-scanning mutagenesis of alpha-helix D segment of interleukin-13 reveals new functionally important residues of the cytokine.
Madhankumar AB; Mintz A; Debinski W
J Biol Chem; 2002 Nov; 277(45):43194-205. PubMed ID: 12189139
[TBL] [Abstract][Full Text] [Related]
39. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
[TBL] [Abstract][Full Text] [Related]
40. Plasma IL13Rα2 as a novel liquid biopsy biomarker for glioblastoma.
Khristov V; Nesterova D; Trifoi M; Clegg T; Daya A; Barrett T; Tufano E; Shenoy G; Pandya B; Beselia G; Smith N; Mrowczynski O; Zacharia B; Waite K; Lathia J; Barnholtz-Sloan J; Connor J
J Neurooncol; 2022 Dec; 160(3):743-752. PubMed ID: 36436150
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
